7HENDERSON C, BERRY D A, DEMETRI G D, et al. Improved outcome from adding sequential paclitaxel but not from escalating doxorubicin does in an adjuvant chemotherapy regimen for patients with node-positive primary breatst cancer[J]. Clin Oncol , 2003,21:976-983.
2[22]Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable bresat cancer[J]. Br J Cancer,1996,74:297
3[23]Fisher B,Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors[J]. J Natl Cancer Inst, 1996,88:1529
4[24]Klijn JGM, Blarney RW, Boccardo F, et al. Combination LHRH-agonist plus tamoxifen treatment is superior to medical castration alone in premenopausal metastatic breast cancer[J]. Breast Cancer Res Treat,1998,50:227(Abst)
5[25]Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol,1998,16:453
6[26]Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carinoma:results of a suvival update based on a combined analysis of data from two mature phase Ⅲ trials[J]. Cancer,1998,83:1142
7[27]Bajetta E, Zilembo N, Barni S, et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse:endocrine and clinical results[J]. Ann Oncol,1997,8:649
8[28]Kaufmann M, Bajetta E, Dirix LY. Survival advantage of exemestane over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen:results of a phase Ⅲ randomized double-blind study[J]. Proc Am Soc Clin Oncol,1999,18:42a
9[29]Crown J, Raptis G, Hamilton N, et al. High-dose chemotherapy of breast cancer:current status and developmental strategies. Eur J Cancer,1995,31A:809
10[30]O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol,1997,125:246
4RAKHA EA, EI-SAYED M E, GREEN A R. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1):25.
5RODRIGUEZ PINILI.A S M, SARRIO D, HONRADO E, et al. Prognostic significance of basal-like phenotype and fasein expression in node-negative invasive breast carcinomas[J]. Clin Cancer Res, 2006,12:1533.
6MINN A J, GUPTA G P, SIEGEL P M, et al. Genes that mediate breast cancer metastasis to lung[J]. Nature, 2005, 436(7050) :518-524.
7IRVIN W J J X, CAREY L A. What is triple-negative breast cancer[J]? Eur J Cancer, 2008,44(18):2799-2805.
8YOUNG S R, ROBERT T P, TALIA D, et al. The prevalence of BRCA1 mutations among young women with triple- negative breast cancer[J]. BMC Cancer, 2009, 9:86.
9KREIKE B, VAN KOUWENHOVE M, HORLINGS H, et al. Gene expression profiling and histopathological characte- rization of triple negative/basal-like breast carcinomas[J]. Breast Cancer Res, 2007,9:R65.
10TAN A R, SWAIN S M. Therapeutic strategies for triplenegative breast cancer[J].Cancer J , 2008,14 (6):343-351.
